Poland HIV Therapeutics Market Analysis Report [2022-30]

Poland HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Poland HIV therapeutics market will reach a value of $xx Mn from $79.81 Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as Polpharma, Polfa Tarchomin, and Adamed. The market is driven by government policies and non-governmental organizations’ initiatives for the management of HIV infections in the country. The HIV therapeutics market in Poland is segmented by type, product, geography, end user, and distribution channel.

ID: IN10PLPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Poland AUTHOR: Dr. Vishwa Modhia

Buy Now

Poland HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Poland HIV therapeutics market will reach a value of $xx Mn from $79.81 Mn in 2022, growing at a CAGR of xx% during 2022-2030.

Poland is a nation in Central Europe that shares borders with Belarus, the Czech Republic, Germany, Lithuania, Russia, Slovakia, and Ukraine. With an age-adjusted death rate of 0.27 per 100,000 people, Poland is ranked 138 in the world. In 2019, Poland's GDP expenditure on healthcare was 6.5%.

The Foundation for Social Education is an NGO that supports HIV patients in Poland. Nearly 1.1 thousand new cases of the human immunodeficiency virus (HIV) were detected in Poland in 2021. Since 2006, when 810 cases were reported, the number of HIV cases has risen in Poland.

Market Dynamics

Market Growth Drivers

The National Health Fund (NFZ), the primary provider of public health insurance in Poland, and the Polish Ministry of Health both have a significant impact on which antiretroviral medications are authorized for use and paid for by patients with HIV. The use of these drugs in Poland is still being driven by the ongoing development of new and more efficient antiretroviral drugs as well as the growing understanding of HIV treatment and management.

Market Restraints

Antiretroviral drug use in Poland may also be constrained by stigma and a lack of knowledge about HIV and its treatment, as people may be reluctant to get tested or treated out of concern for prejudice or ignorance of the condition. This can limit the growth of Poland's HIV therapeutics market.

Competitive Landscape

Key Players

Adamed (POL)
Polfa Tarchomin (POL)
Polpharma (POL)
Santhera Pharmaceuticals (POL)
Viatris (POL)
Pfizer
AstraZeneca
GlaxoSmithKline

Recent Notable Update

December 2022: Legislation was passed by the Polish government to guarantee that these medications are accessible in Poland for the treatment of Ukrainian patients. The majority of Ukrainian refugees who crossed the border were in Poland, where nearly 1.5 Mn people requested temporary shelter. Many of them are receiving treatment and are aware that they are HIV-positive. Some people might not be aware of their status, while others are more likely to get HIV as a result of outside factors like drug use or sexual transmission, including sex work and sexual abuse. The best options for the health of patients from Ukraine involve maintaining adherence to effective treatment regimens and avoiding pointless changes.

Healthcare Regulations and Reimbursement Policies

The Polish Ministry of Health is primarily in charge of regulating antiretroviral medications used to treat HIV in Poland. This ministry is in charge of establishing national standards and regulations for the treatment of HIV, including the authorization and administration of antiretroviral medications. The Polish Agency for Health Technology Assessment and Tariff System (AOTM), in addition to the Ministry of Health, is involved in the regulation of antiretroviral medications used to treat HIV.

The National Health Fund (NFZ), Poland's primary public health insurance provider, typically pays for the antiretroviral medications used to treat HIV in Poland. For those covered by the public health insurance program, the NFZ covers the cost of antiretroviral medications. The amount of reimbursement varies based on the particular medication and the patient's needs. The NFZ generally covers both first-line and second-line antiretroviral regimens for the treatment of HIV.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.